stockrow
Friday 6 November 2026
Export ADAPY’s income statement to Excel — free account
Adaptimmune Therapeutics PLC
ADAPY Healthcare Biotechnology
Adaptimmune Therapeutics PLC’s revenue for fiscal 2025 (year ended December 2025) was $5.9 million, down 96.7% from fiscal 2024.
- Revenue
- −89.3%
- EPS
- −140.7%
- Free cash flow
- −174.7%
Quarter to June 2025, against a year earlier
0.02
0.00
0.00%
Follow ADAPY
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | 14 | 38 | 60 | 1 | 4 | 6 | 27 | 60 | 178 | 6 | (9.3%) | 72 | 157 | — | +415.5% | |
| Gross margin, % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 99.96 | 100.00 | 0.0 pt | ||||||
| EBT | (71) | (70) | (95) | (137) | (130) | (157) | (163) | (113) | (183) | (78) | +1.1% | ||||||
| EBT margin, % | (497.87) | (184.20) | (159.68) | (12,203.48) | (3,282.72) | (2,558.12) | (600.26) | (186.68) | (102.75) | (1,316.78) | (818.9) pt | ||||||
| Net income | (72) | (70) | (96) | (137) | (130) | (158) | (165) | (114) | (71) | 30 | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.20 | 0.43 | 0.61 | 0.01 | 0.03 | 0.04 | 0.17 | 0.30 | 0.71 | 0.02 | (21.6%) | |||||
| Earnings | (1.01) | (0.80) | (0.96) | (1.32) | (0.90) | (1.02) | (1.02) | (0.54) | (0.28) | 0.12 | n/m | ||||||
| Cash flow | (0.68) | (0.62) | (1.07) | (1.07) | (0.38) | 0.07 | (0.88) | (0.70) | (0.29) | (0.46) | (4.2%) | ||||||
| Capex | (0.18) | (0.28) | (0.05) | (0.03) | (0.02) | (0.06) | (0.18) | (0.02) | (0.01) | 0.00 | (53.1%) | ||||||
| Free cash flow | (0.86) | (0.90) | (1.12) | (1.10) | (0.40) | 0.01 | (1.06) | (0.72) | (0.30) | (0.46) | (6.6%) | ||||||
| Book value | 2.35 | 2.31 | 2.54 | 1.18 | 2.40 | 1.32 | 0.51 | 0.20 | 0.05 | 0.12 | (28.0%) | ||||||
| Shares, m | 71 | 88 | 97 | 105 | 142 | 156 | 161 | 201 | 252 | 263 | +15.7% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 20.54 | 16.50 | 9.41 | 48.43 | 194.01 | 95.02 | 9.92 | 2.50 | 0.77 | 0.12 | 39.7 | ||||||
| P/B | 1.76 | 3.08 | 2.27 | 1.02 | 2.25 | 2.84 | 3.29 | 3.82 | 10.45 | 0.00 | 3.1 | ||||||
| EV/Sales | 7.76 | 11.00 | 5.96 | 22.83 | 106.27 | 38.68 | 3.13 | 0.40 | 0.20 | 0.12 | 19.6 | ||||||
| EV/FCF | (1.81) | (5.28) | (3.25) | (0.51) | (7.44) | 122.09 | (0.50) | (0.17) | (0.46) | (0.04) | 10.3 | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | (48) | (54) | (104) | (113) | (54) | 11 | (142) | (141) | (73) | (122) | +10.9% | |||||
| Capex | (13) | (24) | (5) | (3) | (3) | (9) | (30) | (5) | (2) | 0 | (45.9%) | ||||||
| Free cash flow | (61) | (79) | (109) | (116) | (56) | 2 | (172) | (146) | (75) | (122) | +8.0% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | 158 | 156 | 207 | 86 | 359 | 353 | 191 | 135 | 122 | 23 | (19.3%) | |||||
| Net debt | (181) | (208) | (205) | (67) | (347) | (346) | (184) | (147) | (101) | (26) | (19.4%) | ||||||
| Shareholders’ equity | 166 | 203 | 247 | 124 | 341 | 206 | 82 | 40 | 12 | 32 | (16.7%) | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | (26.71) | (27.20) | (34.24) | (59.86) | (41.12) | (34.34) | (41.44) | (37.24) | (27.17) | 16.27 | +43.0 pt | |||||
| ROIC | 0.00 | 0.00 | (123.30) | (153.09) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (753.70) | (753.7) pt | ||||||
| ROE | (33.58) | (38.00) | (42.46) | (74.04) | (55.97) | (57.78) | (114.96) | (187.61) | (273.57) | 112.01 | +145.6 pt | ||||||
| People | |||||||||||||||||
| People | Employees | 298 | 371 | 430 | 400 | 462 | 494 | 534 | 449 | 506 | 272 | (1.0%) | |||||
| Revenue/emp, $m | 0.05 | 0.10 | 0.14 | 0.00 | 0.01 | 0.01 | 0.05 | 0.13 | 0.35 | 0.02 | (8.3%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2025 · fundamentals updated 26 Oct 2026
Adaptimmune Therapeutics PLC vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ABOS Acumen Pharmaceuticals, Inc. | $15.5M | — (loss-making) | — | — | n/m | +12.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CTXR Citius Pharmaceuticals, Inc. | $15.3M | — (loss-making) | — | — | n/m | −60.50% (below 0%: shrinking) | 67.07% | (785.39%) | Compare |
| PLUR Pluri Inc. | $15.0M | — (loss-making) | — (loss-making) | −15.83% (below 0%: shrinking) | n/m | +25.03% (above 0%: growing) | 58.51% | (1,655.52%) | Compare |
| NEUP Neuphoria Therapeutics Inc. | $15.0M | — (loss-making) | — (loss-making) | −107.32% (below 0%: shrinking) | n/m | +133.86% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MRKR MARKER THERAPEUTICS, INC. | $14.9M | — (loss-making) | — (loss-making) | −51.00% (below 0%: shrinking) | n/m | −97.84% (below 0%: shrinking) | 209.68% | 0.00% | Compare |
| KYNB Kyntra Bio Inc | $14.8M | 0.1× | — (loss-making) | −209.35% (below 0%: shrinking) | n/m | −131.50% (below 0%: shrinking) | 100.14% | 1,192.27% | Compare |
| ATYR aTyr Pharma, Inc. | $14.8M | — (loss-making) | — (loss-making) | −90.75% (below 0%: shrinking) | n/m | +32.22% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ADAPY Adaptimmune Therapeutics PLC | $14.6M | — (loss-making) | — (loss-making) | −89.33% (below 0%: shrinking) | n/m | −174.72% (below 0%: shrinking) | 81.71% | (221.45%) | |
| RADX Radiopharm Theranostics Limited - Sponsored ADR | $14.0M | — | — | — | — | −137.75% (below 0%: shrinking) | — | — | Compare |
| Median of peers | $15.0M | — | — | −90.75% | — | −23.96% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 25 April 2025
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2024 | 2.11m | 1.38m | 14.37 |
| 2023 | 2.77m | 1.17m | 21.15 |
| 2022 | 3.41m | 14.57k | 38.93 |
Ownership
Directors and executive officers, together
12.74%
EcoR1 Capital, LLC
10.48%
Long Focus Capital Management, LLC
7.84%
Ali Behbahani, M.D.
6.73%
New Enterprise Associates
6.53%
Two Seas Capital L.P.
5.67%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement